A Phase 3 interventional study of Talazoparib with enzalutamide and Placebo with enzalutamide in mCRPC, sponsored by Pfizer. Active, not recruiting at 370 sites in 26 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.
Part 1 is an open-label, non-randomized, safety and PK run-in study designed to confirm the starting dose of talazoparib in combination with enzalutamide through assessment of target safety events and PK at select sites. Part 2 is a randomized, double-blind, placebo-controlled, multinational study comparing talazoparib plus enzalutamide vs. placebo plus enzalutamide in patients with mCRPC.
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
or cytologically confirmed adenocarcinoma of the prostate without small cell or signet cell features
Asymptomatic or mildly symptomatic castration resistant prostate cancer (mCRPC) (score on BPI-SF Question #3 must be \< 4).
For enrollment into Part 2 only (optional in Part 1): assessment of DDR mutation status
Consent to a saliva sample collection for a germline comparator unless prohibited by local regulations or ethics committee decision (optional for patients in Part 1).
Surgically or medically castrated, with serum testosterone ≤ 50 ng/dL (≤ 1.73 nmol/L) at screening.
Metastatic disease in bone documented on bone scan or in soft tissue documented on CT/MRI scan.
Progressive disease at study entry in the setting of medical or surgical castration as defined by 1 or more of the following 3 criteria:
Ongoing bisphosphonate or denosumab use prior to Day 1 (Part 1) or randomization (Part 2) is allowed but not mandatory.
(ECOG) performance status ≤ 1.
≥ 12 months as assessed by the investigator.
Able to swallow the study drug and have no known intolerance to study drugs or .
Must agree to use a condom when having sex with a partner from the time of the first dose of study drug through 4 months after last dose of study treatment. Must also agree for female partner of to use an additional highly effective form of from the time of the first dose of study treatment through 4 months after last dose of study treatment when having sex with a non pregnant female partner of childbearing potential.
Must agree not to donate sperm from the first dose of study drug to 4 months after the last dose of study drug.
Evidence of a personally signed and dated document (and molecular prescreening consent if appropriate) indicating that the patient [or a legally acceptable representative/legal guardian] has been informed of all pertinent aspects of the study.
Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
Exclusion Criteria:
Any prior systemic cancer treatment initiated in in the non CRPC and mCRPC disease state.
Patients whose only evidence of metastasis is adenopathy below the aortic bifurcation.
Prior treatment with second-generation androgen receptor inhibitors (enzalutamide, apalutamide, and darolutamide), a PARP inhibitor, cyclophosphamide, or mitoxantrone for prostate cancer.
Prior treatment with platinum-based chemotherapy within 6 months (from the last dose) prior to Day 1 (Part 1) or randomization (Part 2), or any history of disease progression on platinum-based therapy within 6 months (from the last dose).
Treatment with cytotoxic chemotherapy, biologic therapy including sipuleucel T, or radionuclide therapy received in the castration-sensitive prostate cancer is NOT exclusionary if discontinued in the 28 days prior to Day 1 (Part 1) or randomization (Part 2).
Treatment with any agent within 4 weeks before Day 1 (Part 1) or randomization (Part 2).
Prior treatment with opioids for pain related to either primary prostate cancer or metastasis within 28 days prior to Day 1 (Part 1) or randomization (Part 2).
Current use of potent P-gp inhibitors within 7 days prior to Day 1 (Part 1) or randomization (Part 2).
Major surgery (as defined by the investigator) within 2 weeks before Day 1 (Part 1) or randomization (Part 2), or palliative localized radiation therapy within 3 weeks before randomization (Part 2).
cardiovascular disease
Significant renal dysfunction as defined by any of the following laboratory abnormalities:
Patients enrolled in Part 1 only: Moderate renal impairment (eGFR 30-59 mL/min/1.73 m2) at screening.
Significant hepatic dysfunction as defined by any of the following laboratory abnormalities on screening labs:
\< 1500/µL, \< 100,000/µL, or \< 9 g/dL (may not have received growth factors or blood transfusions within 14 days before obtaining the hematology values at screening).
Known or suspected or active .
Symptomatic or impending spinal cord compression or cauda equina syndrome.
Any history of myelodysplastic syndrome, acute myeloid leukemia, or prior except any of the following:
Gastrointestinal disorder affecting absorption.
Fertile male subjects who are unwilling or unable to use highly effective methods of for the duration of the study and for 4 months after the last dose of investigational product.
Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or patients who are Pfizer employees, including their family members, directly involved in the conduct of the study.
Other acute or chronic medical (concurrent disease, infection, or comorbidity) or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that interferes with ability to participate in the study, may increase the risk associated with study participation or investigational product administration, or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
History of seizure or any condition that may predispose to seizure (eg, prior cortical stroke, significant brain trauma). Also, history of loss of consciousness or within 12 months of randomization (Part 2).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Talazoparib plus enzalutamide
Drug: Talazoparib with enzalutamide
Ezalutamide plus placebo
Drug: Placebo with enzalutamide
Drug pages: Talazoparib · Enzalutamide
Talazoparib 0.5 mg/day plus enzalutamide 160mg/day
Placebo plus enzalutamide 160 mg/day
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Occuring Within the First 66 Days of Dosing - Part 1
An adverse event (AE) was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are defined as newly occurring AEs or those worsening after first dose. As per Common Terminology Criteria for Adverse Events (CTCAE) version 4, Grade 1= mild AE; Grade 2= moderate AE; Grade 3= severe AE; Grade 4= life-threatening or disabling AE; Grade 5= death related to an AE. Serious TEAE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. SAEs were determined according to the investigator's assessment. Results as of 16 Aug 2022 are reported.
Time frame: Post dose on Day 1 up to Day 66 in Part 1
Number of Participants With All-Causality Clustered Treatment-Emergent Cytopenias by Preferred Term (PT) and Max CTCAE Grade Occuring Within the First 66 Days of Dosing - Part 1
An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are defined as newly occurring AEs or those worsening after first dose. As per CTCAE version 4, Grade 1=mild AE; Grade 2=moderate AE; Grade 3=severe AE; Grade 4=life-threatening or disabling AE; Grade 5=death related to an AE. Medical Dictionary for Regulatory Activities (MedDRA) v25.0 coding dictionary applied. PTs for the cluster terms are: ANEMIA, including Anemia, Hematocrit decreased, Hemoglobin decreased, and Red blood cell count decreased; THROMBOCYTOPENIA, including, Thrombocytopenia and Platelet count decreased; NEUTROPENIA, including Febrile neutropenia, Neutropenia and Neutrophil count decreased; LEUKOPENIA, including Leukopenia, White blood cell count decreased. Events in any grade with at least 1 occurrence in participants are reported for this outcome measure. Results as of 16 Aug 2022 are reported.
Time frame: Post dose on Day 1 up to Day 66 in Part 1
Number of Participants With All-Causality TEAEs During the Overall Period of Part 1
An adverse event (AE) was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are defined as newly occurring AEs or those worsening after first dose. As per CTCAE version 4, Grade 1= mild AE; Grade 2= moderate AE; Grade 3= severe AE; Grade 4= life-threatening or disabling AE; Grade 5= death related to an AE. Serious TEAE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. SAEs were determined according to the investigator's assessment. Results as of 16 Aug 2022 are reported.
Time frame: Post dose on Day 1 up to 28 days after the last dose of study intervention, or before new systemic antineoplastic therapy, whichever occurred first (maximum of 235.14 weeks)
Number of Participants With Treatment-Related TEAEs During the Overall Period of Part 1
An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are defined as newly occurring AEs or those worsening after first dose. Treatment-related AE was any untoward medical occurrence attributed to study intervention in a participant who received study intervention. As per CTCAE version 4, Grade 1= mild AE; Grade 2= moderate AE; Grade 3= severe AE; Grade 4= life-threatening or disabling AE; Grade 5= death related to an AE. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. SAEs were determined according to the investigator's assessment. Results as of 16 Aug 2022 are reported.
Time frame: Post dose on Day 1 up to 28 days after the last dose of study intervention, or before new systemic antineoplastic therapy, whichever occurred first (maximum of 235.14 weeks)
Number of Participants With All-Causality Clustered Treatment-Emergent Cytopenias by PT and Max CTCAE Grade Occuring Anytime After Dosing - Part 1
An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are defined as newly occurring AEs or those worsening after first dose. As per CTCAE version 4, Grade 1=mild AE; Grade 2=moderate AE; Grade 3=severe AE; Grade 4=life-threatening or disabling AE; Grade 5=death related to an AE. MedDRA v25.0 coding dictionary applied. PTs for the cluster terms are: ANEMIA, including Anemia, Hematocrit decreased, Hemoglobin decreased, and Red blood cell count decreased; THROMBOCYTOPENIA, including, Thrombocytopenia and Platelet count decreased; NEUTROPENIA, including Febrile neutropenia, Neutropenia and Neutrophil count decreased; LEUKOPENIA, including Leukopenia, White blood cell count decreased. Events in any grade with at least 1 occurrence in participants are reported for this outcome measure. Results as of 16 Aug 2022 are reported.
Time frame: Post dose on Day 1 up to 28 days after the last dose of study intervention, or before new systemic antineoplastic therapy, whichever occurred first (maximum of 235.14 weeks)
Number of Participants With Treatment-Related Clustered Treatment-Emergent Cytopenias by PT and Max CTCAE Grade in >=10% of Participants Occuring Anytime After Dosing - Part 1
An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are newly occurring AEs or those worsening after first dose. Treatment-related AE was any AE attributed to study intervention in a participant who received study intervention. As per CTCAE version 4, Grade 1=mild; Grade 2=moderate; Grade 3=severe; Grade 4=life-threatening or disabling; Grade 5=death related to an AE. MedDRA v25.0 coding dictionary applied. PTs for the cluster terms are: ANEMIA, including Anemia, Hematocrit decreased, Hemoglobin decreased, and Red blood cell count decreased; THROMBOCYTOPENIA, including, Thrombocytopenia and Platelet count decreased; NEUTROPENIA, including Febrile neutropenia, Neutropenia and Neutrophil count decreased; LEUKOPENIA, including Leukopenia, White blood cell count decreased. Events in any grade with incidence in \>=10% of participants are reported. Results as of 16 Aug 2022 are reported.
Time frame: Post dose on Day 1 up to 28 days after the last dose of study intervention, or before new systemic antineoplastic therapy, whichever occurred first (maximum of 235.14 weeks)
Blinded Independent Central Review (BICR) Assessed Radiographic Progression-Free Survival (rPFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for All-Comers - Part 2 Cohort 1
rPFS is defined as the time from the date of randomization to first objective evidence of radiographic progression as assessed in soft tissue per RECIST 1.1, or death, whichever occurs first. Soft tissue disease status was assessed at regular intervals during the course of the study by computed tomography (CT) of chest and CT or magnetic resonance imaging (MRI) of abdomen and pelvis. Progression is defined using RECIST 1.1 as a \>=20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Results as of 16 Aug 2022 are reported for this outcome measure.
Time frame: From the start of treatment to the time of first documented progression, or death (maximum up to 42 months)
BICR Assessed rPFS Per RECIST 1.1 in Patients With DDR Deficiencies - Part 2
rPFS is defined as the time from the date of randomization to first objective evidence of radiographic progression as assessed in soft tissue per RECIST 1.1, or death, whichever occurs first. Soft tissue disease status was assessed at regular intervals during the course of the study by CT of chest and CT or MRI of abdomen and pelvis. Results as of 03 Oct 2022 are reported for this outcome measure.
Time frame: From the start of treatment to the time of first documented progression, or death (maximum up to 38 months)
As of the data cutoff for the primary completion date (PCD) on 16 Aug 2022 for Part 1 and Part 2 Cohort 1 and on 03 Oct 2022 for Part 2 Cohort 2, for overall study, 2896 participants were screened for participation in the C3441021 study. As of 03 Oct 2022, a total of 1054 participants were enrolled in this study.
| Milestone | Part 1: Talazoparib 1 mg QD+Enzalutamide | Part 1: Talazoparib 0.5 mg QD+Enzalutamide | Part 2 Cohort 1: Talazoparib+Enzalutamide (All-comer) | Part 2 Cohort 1: Placebo+Enzalutamide (All-comer) | Part 2 Cohort 2: Talazoparib+Enzalutamide (DDR-deficient) | Part 2 Cohort 2: Placebo+Enzalutamide (DDR-deficient) |
|---|---|---|---|---|---|---|
| Started | 13 | 6 | 402 | 403 | 115 | 115 |
| Completed | 13 | 6 | 402 | 403 | 115 | 115 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Talazoparib 1 mg QD+Enzalutamide | Part 1: Talazoparib 0.5 mg QD+Enzalutamide | Part 2 Cohort 1: Talazoparib+Enzalutamide (All-comer) | Part 2 Cohort 1: Placebo+Enzalutamide (All-comer) | Part 2 Cohort 2: Talazoparib+Enzalutamide (DDR-deficient) | Part 2 Cohort 2: Placebo+Enzalutamide (DDR-deficient) |
|---|---|---|---|---|---|---|
| Started | 13 | 6 | 402 | 403 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 13 | 6 | 402 | 403 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 8 | 10 | 0 | 0 |
| Withdrew: No longer meets eligibility ceriteria | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: No longer clinically benefiting | 0 | 0 | 14 | 21 | 0 | 0 |
| Withdrew: Not treated with talazoparib | 0 | 0 | 5 | 3 | 0 | 0 |
| Withdrew: Adverse event | 9 | 3 | 69 | 43 | 0 | 0 |
| Withdrew: Progressive disease | 1 | 1 | 76 | 124 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 29 | 30 | 0 | 0 |
| Withdrew: Global deterioration of health status | 1 | 0 | 44 | 46 | 0 | 0 |
| Withdrew: Other | 1 | 1 | 4 | 5 | 0 | 0 |
| Withdrew: Ongoing | 1 | 0 | 152 | 120 | 0 | 0 |
| Milestone | Part 1: Talazoparib 1 mg QD+Enzalutamide | Part 1: Talazoparib 0.5 mg QD+Enzalutamide | Part 2 Cohort 1: Talazoparib+Enzalutamide (All-comer) | Part 2 Cohort 1: Placebo+Enzalutamide (All-comer) | Part 2 Cohort 2: Talazoparib+Enzalutamide (DDR-deficient) | Part 2 Cohort 2: Placebo+Enzalutamide (DDR-deficient) |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 200 | 199 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 200 | 199 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 | 4 |
| Withdrew: No longer clinically benefiting | 0 | 0 | 0 | 0 | 5 | 8 |
| Withdrew: Not treated with talazoparib | 0 | 0 | 0 | 0 | 3 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 19 | 11 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 0 | 39 | 60 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 11 | 13 |
| Withdrew: Global deterioration of health status | 0 | 0 | 0 | 0 | 24 | 40 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 3 | 3 |
| Withdrew: Ongoing | 0 | 0 | 0 | 0 | 95 | 60 |
An adverse event (AE) was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are defined as newly occurring AEs or those worsening after first dose. As per Common Terminology Criteria for Adverse Events (CTCAE) version 4, Grade 1= mild AE; Grade 2= moderate AE; Grade 3= severe AE; Grade 4= life-threatening or disabling AE; Grade 5= death related to an AE. Serious TEAE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. SAEs were determined according to the investigator's assessment. Results as of 16 Aug 2022 are reported.
| Participants | Part 1: Talazoparib 1 mg QD+Enzalutamide | Part 1: Talazoparib 0.5 mg QD+Enzalutamide |
|---|---|---|
| Participants with TEAEs | 13 | 6 |
| Participants with medication error TEAE | 0 | 0 |
| Participants with serious TEAE | 1 | 0 |
| Participants with Maximum Grade 3 or 4 TEAE | 8 | 1 |
| Participants with Maximum Grade 5 TEAE | 0 | 0 |
An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are defined as newly occurring AEs or those worsening after first dose. As per CTCAE version 4, Grade 1=mild AE; Grade 2=moderate AE; Grade 3=severe AE; Grade 4=life-threatening or disabling AE; Grade 5=death related to an AE. Medical Dictionary for Regulatory Activities (MedDRA) v25.0 coding dictionary applied. PTs for the cluster terms are: ANEMIA, including Anemia, Hematocrit decreased, Hemoglobin decreased, and Red blood cell count decreased; THROMBOCYTOPENIA, including, Thrombocytopenia and Platelet count decreased; NEUTROPENIA, including Febrile neutropenia, Neutropenia and Neutrophil count decreased; LEUKOPENIA, including Leukopenia, White blood cell count decreased. Events in any grade with at least 1 occurrence in participants are reported for this outcome measure. Results as of 16 Aug 2022 are reported.
| Participants | Part 1: Talazoparib 1 mg QD+Enzalutamide | Part 1: Talazoparib 0.5 mg QD+Enzalutamide |
|---|---|---|
| Grade 2 Anemia | 2 | 0 |
| Grade 3 Anemia | 6 | 1 |
| Grade 1 Neutropenia | 1 | 0 |
| Grade 2 Neutropenia | 1 | 0 |
| Grade 3 Neutropenia | 4 | 0 |
| Grade 2 Leukopenia | 1 | 0 |
| Grade 3 Leukopenia | 3 | 0 |
| Grade 3 Thrombocytopenia | 2 | 0 |
An adverse event (AE) was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are defined as newly occurring AEs or those worsening after first dose. As per CTCAE version 4, Grade 1= mild AE; Grade 2= moderate AE; Grade 3= severe AE; Grade 4= life-threatening or disabling AE; Grade 5= death related to an AE. Serious TEAE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. SAEs were determined according to the investigator's assessment. Results as of 16 Aug 2022 are reported.
| Participants | Part 1: Talazoparib 1 mg QD+Enzalutamide | Part 1: Talazoparib 0.5 mg QD+Enzalutamide |
|---|---|---|
| Participants with TEAEs | 13 | 6 |
| Participants with medication error TEAE | 0 | 0 |
| Participants with serious TEAE | 6 | 3 |
| Participants with Maximum Grade 3 or 4 TEAE | 11 | 6 |
| Participants with Maximum Grade 5 TEAE | 1 | 0 |
An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are defined as newly occurring AEs or those worsening after first dose. Treatment-related AE was any untoward medical occurrence attributed to study intervention in a participant who received study intervention. As per CTCAE version 4, Grade 1= mild AE; Grade 2= moderate AE; Grade 3= severe AE; Grade 4= life-threatening or disabling AE; Grade 5= death related to an AE. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. SAEs were determined according to the investigator's assessment. Results as of 16 Aug 2022 are reported.
| Participants | Part 1: Talazoparib 1 mg QD+Enzalutamide | Part 1: Talazoparib 0.5 mg QD+Enzalutamide |
|---|---|---|
| Participants with TEAEs | 13 | 6 |
| Participants with medication error TEAE | 0 | 0 |
| Participants with serious TEAE | 2 | 1 |
| Participants with Maximum Grade 3 or 4 TEAE | 10 | 4 |
| Participants with Maximum Grade 5 TEAE | 1 | 0 |
An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are defined as newly occurring AEs or those worsening after first dose. As per CTCAE version 4, Grade 1=mild AE; Grade 2=moderate AE; Grade 3=severe AE; Grade 4=life-threatening or disabling AE; Grade 5=death related to an AE. MedDRA v25.0 coding dictionary applied. PTs for the cluster terms are: ANEMIA, including Anemia, Hematocrit decreased, Hemoglobin decreased, and Red blood cell count decreased; THROMBOCYTOPENIA, including, Thrombocytopenia and Platelet count decreased; NEUTROPENIA, including Febrile neutropenia, Neutropenia and Neutrophil count decreased; LEUKOPENIA, including Leukopenia, White blood cell count decreased. Events in any grade with at least 1 occurrence in participants are reported for this outcome measure. Results as of 16 Aug 2022 are reported.
| Participants | Part 1: Talazoparib 1 mg QD+Enzalutamide | Part 1: Talazoparib 0.5 mg QD+Enzalutamide |
|---|---|---|
| Grade 3 Anemia | 10 | 3 |
| Grade 1 Neutropenia | 1 | 0 |
| Grade 2 Neutropenia | 1 | 0 |
| Grade 3 Neutropenia | 6 | 0 |
| Grade 2 Leukopenia | 1 | 0 |
| Grade 3 Leukopenia | 5 | 0 |
| Grade 3 Thrombocytopenia | 3 | 0 |
| Grade 4 Anemia | 0 | 1 |
| Grade 2 Lymphopenia | 1 | 0 |
| Grade 3 Lymphopenia | 2 | 0 |
An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are newly occurring AEs or those worsening after first dose. Treatment-related AE was any AE attributed to study intervention in a participant who received study intervention. As per CTCAE version 4, Grade 1=mild; Grade 2=moderate; Grade 3=severe; Grade 4=life-threatening or disabling; Grade 5=death related to an AE. MedDRA v25.0 coding dictionary applied. PTs for the cluster terms are: ANEMIA, including Anemia, Hematocrit decreased, Hemoglobin decreased, and Red blood cell count decreased; THROMBOCYTOPENIA, including, Thrombocytopenia and Platelet count decreased; NEUTROPENIA, including Febrile neutropenia, Neutropenia and Neutrophil count decreased; LEUKOPENIA, including Leukopenia, White blood cell count decreased. Events in any grade with incidence in \>=10% of participants are reported. Results as of 16 Aug 2022 are reported.
| Participants | Part 1: Talazoparib 1 mg QD+Enzalutamide | Part 1: Talazoparib 0.5 mg QD+Enzalutamide |
|---|---|---|
| Grade 3 Anemia | 10 | 3 |
| Grade 1 Neutropenia | 1 | 0 |
| Grade 2 Neutropenia | 1 | 0 |
| Grade 3 Neutropenia | 6 | 0 |
| Grade 2 Leukopenia | 2 | 0 |
| Grade 3 Leukopenia | 4 | 0 |
| Grade 3 Thrombocytopenia | 3 | 0 |
| Grade 4 Anemia | 0 | 1 |
| Grade 2 Lymphopenia | 1 | 0 |
| Grade 3 Lymphopenia | 2 | 0 |
rPFS is defined as the time from the date of randomization to first objective evidence of radiographic progression as assessed in soft tissue per RECIST 1.1, or death, whichever occurs first. Soft tissue disease status was assessed at regular intervals during the course of the study by computed tomography (CT) of chest and CT or magnetic resonance imaging (MRI) of abdomen and pelvis. Progression is defined using RECIST 1.1 as a \>=20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Results as of 16 Aug 2022 are reported for this outcome measure.
| Months | Part 2 Cohort 1: Talazoparib+Enzalutamide | Part 2 Cohort 1: Placebo+Enzalutamide |
|---|---|---|
| Blinded Independent Central Review (BICR) Assessed Radiographic Progression-Free Survival (rPFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for All-Comers - Part 2 Cohort 1 | NA (27.5 to NA) | 21.9 (16.6 to 25.1) |
rPFS is defined as the time from the date of randomization to first objective evidence of radiographic progression as assessed in soft tissue per RECIST 1.1, or death, whichever occurs first. Soft tissue disease status was assessed at regular intervals during the course of the study by CT of chest and CT or MRI of abdomen and pelvis. Results as of 03 Oct 2022 are reported for this outcome measure.
| Months | Part 2 Participants With DDR Deficiencies: Talazoparib+Enzalutamide | Part 2 Participants With DDR Deficiencies: Placebo+Enzalutamide |
|---|---|---|
| BICR Assessed rPFS Per RECIST 1.1 in Patients With DDR Deficiencies - Part 2 | NA (21.9 to NA) | 13.8 (11.0 to 16.7) |
Collected over Post first dose of any study intervention through 28 days after the last dose of study intervention (up to a maximum of 236 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Talazoparib 1 mg QD+Enzalutamide | 5/13 (38.5%) | 6/13 (46.2%) | 13/13 (100%) |
| Part 1: Talazoparib 0.5 mg QD+Enzalutamide | 2/6 (33.3%) | 3/6 (50%) | 6/6 (100%) |
| Part 2 Cohort 1: Talazoparib+Enzalutamide (All-comer) | 123/402 (30.6%) | 157/398 (39.4%) | 377/398 (94.7%) |
| Part 2 Cohort 1: Placebo+Enzalutamide (All-comer) | 129/403 (32%) | 107/401 (26.7%) | 351/401 (87.5%) |
| Part 2 Participants With DDR Deficiencies: Talazoparib+Enzalutamide | 43/200 (21.5%) | 60/198 (30.3%) | 190/198 (96%) |
| Part 2 Participants With DDR Deficiencies: Placebo+Enzalutamide | 53/199 (26.6%) | 40/199 (20.1%) | 182/199 (91.5%) |
| Event | Part 1: Talazoparib 1 mg QD+Enzalutamide | Part 1: Talazoparib 0.5 mg QD+Enzalutamide | Part 2 Cohort 1: Talazoparib+Enzalutamide (All-comer) | Part 2 Cohort 1: Placebo+Enzalutamide (All-comer) | Part 2 Participants With DDR Deficiencies: Talazoparib+Enzalutamide | Part 2 Participants With DDR Deficiencies: Placebo+Enzalutamide |
|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/13 | 1/6 | 55/398 | 1/401 | 17/198 | 2/199 |
| CholecystitisHepatobiliary disorders | 0/13 | 1/6 | 1/398 | 2/401 | 1/198 | 0/199 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/13 | 1/6 | 0/398 | 0/401 | 0/198 | 0/199 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/13 | 1/6 | 6/398 | 2/401 | 2/198 | 1/199 |
| Aortic thrombosisVascular disorders | 0/13 | 1/6 | 0/398 | 0/401 | 0/198 | 0/199 |
| Cardiac failureCardiac disorders | 1/13 | 0/6 | 1/398 | 2/401 | 0/198 | 1/199 |
| DiverticulitisInfections and infestations | 1/13 | 0/6 | 1/398 | 1/401 | 0/198 | 0/199 |
| Infectious pleural effusionInfections and infestations | 1/13 | 0/6 | 0/398 | 0/401 | 0/198 | 0/199 |
| PneumoniaInfections and infestations | 1/13 | 0/6 | 4/398 | 1/401 | 1/198 | 1/199 |
| Pneumonia necrotisingInfections and infestations | 1/13 | 0/6 | 0/398 | 0/401 | 0/198 | 0/199 |
| Event | Part 1: Talazoparib 1 mg QD+Enzalutamide | Part 1: Talazoparib 0.5 mg QD+Enzalutamide | Part 2 Cohort 1: Talazoparib+Enzalutamide (All-comer) | Part 2 Cohort 1: Placebo+Enzalutamide (All-comer) | Part 2 Participants With DDR Deficiencies: Talazoparib+Enzalutamide | Part 2 Participants With DDR Deficiencies: Placebo+Enzalutamide |
|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 5/13 | 5/6 | 134/398 | 118/401 | 66/198 | 53/199 |
| AnaemiaBlood and lymphatic system disorders | 10/13 | 4/6 | 258/398 | 70/401 | 127/198 | 30/199 |
| Neutrophil count decreasedInvestigations | 8/13 | 0/6 | 142/398 | 28/401 | 64/198 | 13/199 |
| NauseaGastrointestinal disorders | 7/13 | 2/6 | 81/398 | 50/401 | 40/198 | 34/199 |
| Decreased appetiteMetabolism and nutrition disorders | 7/13 | 3/6 | 86/398 | 63/401 | 40/198 | 28/199 |
| DiarrhoeaGastrointestinal disorders | 3/13 | 3/6 | 57/398 | 55/401 | 24/198 | 22/199 |
| Influenza like illnessGeneral disorders | 1/13 | 3/6 | 5/398 | 10/401 | 2/198 | 4/199 |
| FallInjury, poisoning and procedural complications | 4/13 | 3/6 | 68/398 | 58/401 | 24/198 | 24/199 |
| White blood cell count decreasedInvestigations | 6/13 | 0/6 | 88/398 | 18/401 | 37/198 | 15/199 |
| VomitingGastrointestinal disorders | 5/13 | 1/6 | 28/398 | 22/401 | 15/198 | 10/199 |
Included all participants who received at least 1 dose of study treatment (talazoparib or enzalutamide) in Part 1, and all participants who were randomized to double-blind study treatment in Part 2 regardless of whether or not treatment was administered.
| Age, Customized(Participants) | Part 1: Talazoparib 1 mg QD+Enzalutamide | Part 1: Talazoparib 0.5 mg QD+Enzalutamide | Part 2 Cohort 1: Talazoparib+Enzalutamide (All-comer) | Part 2 Cohort 1: Placebo+Enzalutamide (All-comer) | Part 2 Cohort 2: Talazoparib+Enzalutamide (DDR-deficient) | Part 2 Cohort 2: Placebo+Enzalutamide (DDR-deficient) | Total |
|---|---|---|---|---|---|---|---|
| <65 years | 1 | 2 | 79 | 94 | 25 | 26 | 227 |
| 65-<75 years | 8 | 4 | 188 | 175 | 53 | 55 | 483 |
| >=75 years | 4 | 0 | 135 | 134 | 37 | 34 | 344 |
| Sex: Female, Male(Participants) | Part 1: Talazoparib 1 mg QD+Enzalutamide | Part 1: Talazoparib 0.5 mg QD+Enzalutamide | Part 2 Cohort 1: Talazoparib+Enzalutamide (All-comer) | Part 2 Cohort 1: Placebo+Enzalutamide (All-comer) | Part 2 Cohort 2: Talazoparib+Enzalutamide (DDR-deficient) | Part 2 Cohort 2: Placebo+Enzalutamide (DDR-deficient) | Total |
|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 13 | 6 | 402 | 403 | 115 | 115 | 1054 |
| Race/Ethnicity, Customized(Participants) | Part 1: Talazoparib 1 mg QD+Enzalutamide | Part 1: Talazoparib 0.5 mg QD+Enzalutamide | Part 2 Cohort 1: Talazoparib+Enzalutamide (All-comer) | Part 2 Cohort 1: Placebo+Enzalutamide (All-comer) | Part 2 Cohort 2: Talazoparib+Enzalutamide (DDR-deficient) | Part 2 Cohort 2: Placebo+Enzalutamide (DDR-deficient) | Total |
|---|---|---|---|---|---|---|---|
| White | 12 | 6 | 243 | 255 | 88 | 90 | 694 |
| Black or African American | 0 | 0 | 11 | 5 | 4 | 3 | 23 |
| Asian | 0 | 0 | 127 | 120 | 13 | 12 | 272 |
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 2 | 1 | 1 | 0 | 4 |
| Not Reported | 0 | 0 | 19 | 21 | 8 | 10 | 58 |
| Unknown | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Multiracial | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
Showing the first 100 of 370 sites across 26 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Dec 2017 to primary completion in Oct 2022, 57 months.
Results were first posted in Jan 2024, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Talazoparib · Enzalutamide